20 Jul March Biosciences
Gurpreet Ratra, Chief Business Officer
Oct. 6 | 2:30pm | FLW Ballroom F
Houston, TX
(Private)
March Biosciences, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children’s Hospital), is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 2 clinical development for patients with relapsed/refractory T-cell lymphoma. March has a pipeline of assets including novel approaches to solid tumor targeting using a novel synapse stabilizing receptor. The company has raised over $55 million to date, inclusive of venture financing, support from the Cancer Prevention & Research Institute of Texas (CPRIT), and the NIH SBIR program.